Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery […]